{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:34:23Z","timestamp":1790847263032,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["ejinme.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.ejim.2016.11.011","type":"journal-article","created":{"date-parts":[[2016,12,2]],"date-time":"2016-12-02T16:00:56Z","timestamp":1480694456000},"page":"49-54","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"special_numbering":"C","title":["Factors related to the development of acquired von Willebrand syndrome in patients with essential thrombocythemia and polycythemia vera"],"prefix":"10.1016","volume":"41","author":[{"given":"A.","family":"Rottenstreich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Kleinstern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Krichevsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Varon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Lavie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Kalish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2016.11.011_bb0005","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1182\/blood-2014-06-528406","article-title":"von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends","volume":"125","author":"Lenting","year":"2015","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.ejim.2016.11.011_bb0010","first-page":"345","article-title":"Acquired von Willebrand syndrome: data from an international registry","volume":"84","author":"Federici","year":"2000","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ejim.2016.11.011_bb0015","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1002\/ajh.20830","article-title":"Acquired von Willebrand syndrome: an update","volume":"82","author":"Franchini","year":"2007","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ejim.2016.11.011_bb0020","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/ajh.2830260204","article-title":"Acquired von Willebrand disease in patients with polycythemia rubra vera","volume":"26","author":"Mohri","year":"1987","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ejim.2016.11.011_bb0025","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1182\/blood.V91.10.3623","article-title":"Clinical significance of inhibitors in acquired von Willebrand syndrome","volume":"91","author":"Mohri","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2016.11.011_bb0030","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1182\/blood.V82.6.1749.1749","article-title":"Elevated platelet count as a cause of abnormal von Willebrand factor multimer distribution in plasma","volume":"82","author":"Budde","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2016.11.011_bb0035","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1046\/j.1365-2141.1996.d01-1729.x","article-title":"The reduction of large von Willebrand factor multimers in plasma in essential thrombocythaemia is related to the platelet count","volume":"93","author":"van Genderen","year":"1996","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejim.2016.11.011_bb0040","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1046\/j.1365-2141.1997.4823285.x","article-title":"Decreased half-life time of plasma von Willebrand factor collagen binding activity in essential thrombocythaemia: normalization after cytoreduction of the increased platelet count","volume":"99","author":"van Genderen","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejim.2016.11.011_bb0045","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1182\/blood-2012-04-424911","article-title":"Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort","volume":"120","author":"Campbell","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2016.11.011_bb0050","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/leu.2011.258","article-title":"Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria","volume":"26","author":"Finazzi","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.ejim.2016.11.011_bb0055","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1182\/blood-2006-05-025544","article-title":"Management of extreme thrombocytosis in otherwise low-risk essential thrombocythemia; does number matter?","volume":"108","author":"Tefferi","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2016.11.011_bb0060","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/ajh.21730","article-title":"Polycythemia vera-associated acquired von Willebrand syndrome despite near-normal platelet count","volume":"85","author":"Tefferi","year":"2010","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ejim.2016.11.011_bb0065","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1038\/leu.2013.99","article-title":"Personalized management of essential thrombocythemia-application of recent evidence to clinical practice","volume":"27","author":"Tefferi","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.ejim.2016.11.011_bb0070","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/ajh.23895","article-title":"Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification, and management","volume":"90","author":"Tefferi","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ejim.2016.11.011_bb0075","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2007-04-083501","article-title":"Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel","volume":"110","author":"Tefferi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2016.11.011_bb0080","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/j.1538-7836.2008.02909.x","article-title":"Diagnostic workup of patients with acquired von Willebrand syndrome: a retrospective single-centre cohort study","volume":"6","author":"Tiede","year":"2008","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ejim.2016.11.011_bb0085","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1160\/TH14-02-0108","article-title":"Performance of two new automated assays for measuring von Willebrand activity:HemosIL AcuStar and Innovance","volume":"112","author":"de Maistre","year":"2014","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ejim.2016.11.011_bb0090","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/hae.12380","article-title":"Diagnosis of inherited von Willebrand disease: comparison of two methodologies and analysis of the discrepancies","volume":"20","author":"Costa-Pinto","year":"2014","journal-title":"Haemophilia"},{"issue":"10","key":"10.1016\/j.ejim.2016.11.011_bb0095","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","article-title":"JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes","volume":"123","author":"Rumi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2016.11.011_bb0100","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ejim.2016.11.011_bb0105","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1055\/s-2006-949664","article-title":"The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera","volume":"32","author":"Michiels","year":"2006","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.ejim.2016.11.011_bb0110","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1111\/jth.12967","article-title":"Qualitative and quantitative modifications of von Willebrand factor in patients with essential thrombocythemia and controlled platelet count","volume":"13","author":"Lancellotti","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ejim.2016.11.011_bb0115","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1182\/asheducation-2011.1.208","article-title":"Genetic and epigenetic complexity in myeloproliferative neoplasms","volume":"2011","author":"Cross","year":"2011","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.ejim.2016.11.011_bb0120","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/ajh.21338","article-title":"Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: relationship with thrombosis occurrence and JAK2 V617F allele burden","volume":"84","author":"Reverter","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ejim.2016.11.011_bb0125","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1073\/pnas.1312148111","article-title":"JAK2V617F-positive endothelial cells contribute to clotting abnormalities in myeloproliferative neoplasms","volume":"111","author":"Etheridge","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ejim.2016.11.011_bb0130","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.thromres.2015.07.029","article-title":"Factors predisposing to acquired von Willebrand syndrome during the course of polycythemia vera \u2013 retrospective analysis of 142 consecutive cases","volume":"136","author":"Mital","year":"2015","journal-title":"Thromb Res"},{"key":"10.1016\/j.ejim.2016.11.011_bb0135","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1182\/blood.V88.8.2939.bloodjournal8882939","article-title":"Shear-dependent changes in the three dimensional structure of human von Willebrand factor","volume":"88","author":"Siedlecki","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2016.11.011_bb0140","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1016\/j.bpj.2008.12.3900","article-title":"Fluid shear induces conformation change in human blood protein von Willebrand factor in solution","volume":"96","author":"Singh","year":"2009","journal-title":"Biophys J"},{"key":"10.1016\/j.ejim.2016.11.011_bb0145","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1126\/science.1170905","article-title":"Mechanoenzymatic cleavage of the ultralarge vascular protein von Willebrand factor","volume":"324","author":"Zhang","year":"2009","journal-title":"Science"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620516304071?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620516304071?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,27]],"date-time":"2020-09-27T18:15:30Z","timestamp":1601230530000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620516304071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":29,"alternative-id":["S0953620516304071"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2016.11.011","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Factors related to the development of acquired von Willebrand syndrome in patients with essential thrombocythemia and polycythemia vera","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2016.11.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}